Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial

Biomarkers have proven their ability in the evaluation of cardiopulmonary diseases. We investigated the utility of concentrations of the biomarker procalcitonin (PCT) alone and with clinical variables for the diagnosis of pneumonia in patients presenting to emergency departments (EDs) with a chief complaint of shortness of breath.

[1]  J. Vestbo,et al.  The prognostic importance of lung function in patients admitted with heart failure , 2010, European journal of heart failure.

[2]  P. Ponikowski,et al.  Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. , 2010, Journal of the American College of Cardiology.

[3]  P. Ponikowski,et al.  Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine , 2010, European journal of heart failure.

[4]  M. Meisner.  Procalcitonin : biochemistry and clinical diagnosis , 2010 .

[5]  T. Bregenzer,et al.  Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. , 2009, JAMA.

[6]  T. Bregenzer,et al.  Effect of procalcitonin-based guidelines compared with standard guidelines on antibiotic use in lower respiratory tract infections: the randomized-controlled multicenter ProHOSP trial , 2009, Critical Care.

[7]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[8]  M. Christ-Crain,et al.  Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia , 2007, BMC infectious diseases.

[9]  B. Guery,et al.  A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit , 2006, Intensive Care Medicine.

[10]  黄亚明,et al.  European Society of Intensive Care Medicine , 2005, Intensive Care Medicine.

[11]  M. Christ-Crain,et al.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial , 2004, The Lancet.

[12]  M. Pfisterer,et al.  Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. , 2004, The New England journal of medicine.

[13]  John G. Bartlett,et al.  Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  R. Menéndez,et al.  Influence of deviation from guidelines on the outcome of community-acquired pneumonia. , 2002, Chest.

[15]  Margaret T May,et al.  Regression Modelling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. Frank E Harrell Jr, New York: Springer 2001, pp. 568, $79.95. ISBN 0-387-95232-2. , 2002 .

[16]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[17]  R. Wuerz,et al.  Effects of prehospital medications on mortality and length of stay in congestive heart failure. , 1992, Annals of emergency medicine.

[18]  M. Fine,et al.  Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study. , 1990, The American journal of medicine.